Biomarkers
AssigneeOtago Innovation Limited
InventorsChristopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
Life of this patent
Estimating the term…
Abstract
The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.
Claims40
An assay for a ghrelin signal peptide (SEQ ID NO:15) fragment, comprising:
- (a) binding one or more immunoreactive ghrelin signal peptides from a biological sample, wherein the biological sample is blood, plasma or serum;
- and
- (b) measuring the level of bound immunoreactive GRN-SP.
A method for predicting, diagnosing or monitoring a biological event or disorder in a subject wherein the event or disorder correlates with the release of immunoreactive ghrelin signal peptide into the circulation, the method comprising:
- (a) measuring the level of immunoreactive ghrelin signal peptide in a biological sample from the subject;
- and
- (b) comparing the level of immunoreactive ghrelin signal peptide with the immunoreactive ghrelin signal peptide level from a control,
- wherein a deviation in the measured level from the control level is indicative of a biological event or disorder that correlates with the release of immunoreactive ghrelin signal peptide.
A method for predicting, diagnosing or monitoring diabetes, or diabetic potential in a subject, the method comprising:
- (a) measuring the level of immunoreactive ghrelin signal peptide in a biological sample from the subject;
- and
- (b) comparing the level of said immunoreactive ghrelin signal peptide with the immunoreactive ghrelin signal peptide level from a control,
- wherein a measured level of immunoreactive ghrelin signal peptide lower than the control level is indicative of diabetes or a predisposition to diabetes.
A method for assessing dysglycemia in a subject, the method comprising:
- (a) measuring the level of immunoreactive ghrelin signal peptide in a subject after administration of glucose;
- and
- (b) comparing the level of said immunoreactive ghrelin signal peptide with the immunoreactive ghrelin signal peptide level from a control,
- wherein a deviation in the measured level of immunoreactive ghrelin signal peptide from the control level is indicative of a glucose handling disorder.
A method for predicting, diagnosing or monitoring an acute cardiac disorder (ACD) in a subject, the method comprising:
- (a) measuring the level of immunoreactive ghrelin signal peptide in a biological sample from the subject;
- and
- (b) comparing the level of said immunoreactive ghrelin signal peptide with the immunoreactive GRN-SP level from a control,
- wherein a measured level of immunoreactive ghrelin signal peptide higher than the control level is indicative of ACD.
Dependencies are inferred from the claim text.